S-1: Aspire Biopharma Registers 147M Shares for Resale

Aspire Biopharma Holdings, Inc. filed an S-1 registration statement for the resale of up to 147 million common shares underlying convertible promissory notes, while reporting significant losses and a going concern doubt.

Summary

• Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.) is an early-stage biopharmaceutical and supplements company focused on novel sublingual delivery mechanisms.
• The company is registering up to 147,177,424 shares of common stock for resale by selling shareholders, which are issuable upon conversion of convertible promissory notes.
• These notes have an aggregate principal amount of $9,687,500, a subscription price of $7,750,000, and a maturity date of February 19, 2026, with a 20% original issue discount and no interest rate.
• Initial funding of $4,709,677 was received on August 19, 2025, with subsequent tranches of $1,000,000 and $2,250,000 contingent on filing and registration statement effectiveness, respectively.
• The conversion price of the notes is the greater of 80% of the lowest closing price during the five trading days prior to conversion or a floor price of $0.0839 per share.
• As of September 17, 2025, the outstanding balance of the notes was $5,887,097, potentially convertible into up to 73,588,712 shares at the floor price.
• A clinical trial for the high-dose sublingual aspirin product concluded in July 2025, with the final report received on September 5, 2025, showing faster bloodstream entry and more significant platelet inhibition than conventional aspirin.
• Aspire plans to submit a section 505(b)(2) NDA for its high-dose aspirin product in Q3 2025 and seek fast-track approval.
• The company has developed formulations for sublingual melatonin, vitamins D, E, K, testosterone, and semaglutide, and has launched caffeine products under its Buzz Bomb Caffeine Co. LC subsidiary.
• Aspire reported an accumulated deficit of $20,699,854 and a working capital deficit of $9,567,500 as of June 30, 2025, with a net loss of $17,922,621 for the six months ended June 30, 2025.
• Management has identified material weaknesses in internal control over financial reporting and expressed substantial doubt about the company's ability to continue as a going concern.
• The company received Nasdaq notices on April 16, 2025, for failing to meet the minimum $50,000,000 Market Value of Listed Securities and $1.00 minimum bid price requirements, with a compliance deadline of October 13, 2025.
• Shareholder approval is being sought for the issuance of more than 19.99% of outstanding shares upon note conversion and for a potential reverse stock split (1-for-5 to 1-for-40 ratio).
• The company will not receive any proceeds from the resale of shares by the selling shareholders.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including substantial doubt about its ability to continue as a going concern, significant accumulated and recurring losses, and a critical working capital deficit. Nasdaq delisting is a near-term risk. While product development shows some promise, the financial foundation is extremely weak, and current financing efforts (like the ELOC) are hampered by low stock price. The S-1 itself is for resale by existing investors, not a primary capital raise for the company, further highlighting the lack of direct cash infusion from this specific filing.

Positives

• Successfully completed a clinical trial for high-dose sublingual aspirin, demonstrating faster bloodstream entry and more significant platelet inhibition (TxB2) compared to standard oral aspirin, with no adverse reactions.
• Management believes the clinical trial results for sublingual aspirin are very positive, supporting future FDA approval.
• Plans to submit a section 505(b)(2) New Drug Application (NDA) for high-dose aspirin in Q3 2025 and seek fast-track approval, leveraging aspirin's long history of safety.
• Developed working formulations for several new sublingual products including melatonin, vitamins D, E, K, testosterone, and semaglutide, expanding its product pipeline.
• Successfully launched Buzz Bomb Caffeine Co. LC products online in August 2025 and secured a second manufacturing agreement for 2,000,000 units, indicating initial commercialization efforts in the supplements market.
• New patent applications (PCT/US2024/022318 and 63/702,381) are pending for its aspirin formulation technology, with nominal expirations in 2044 and 2045, respectively.
• Management is preparing an omnibus patent to extend intellectual property rights to cover many other classes of drugs and supplements, anticipated in Q3 2025.

Negatives

• Reported a net loss of $17,922,621 for the six months ended June 30, 2025, and an accumulated deficit of $20,699,854, indicating significant ongoing financial losses.
• Has a working capital deficit of $9,567,500 and cash of only $206,233 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Received two Nasdaq notices on April 16, 2025, for non-compliance with the minimum $50,000,000 Market Value of Listed Securities and $1.00 minimum bid price requirements, facing potential delisting.
• Previous intellectual property related to Instaprin, including patent applications and a trademark, has expired or been cancelled, despite management's intent to build upon them.
• The Equity Line of Credit (ELOC) agreement with Arena Business Solutions Global SPC II, Ltd. is unlikely to provide increased liquidity due to the current market price being below the $4.00 floor price.
• The company will not receive any proceeds from the sale of shares by the selling shareholders in this registration, limiting its ability to address liquidity issues through this offering.
• Significant dilution risk for existing shareholders due to the potential conversion of up to 147,177,424 shares from convertible notes and the proposed reverse stock split.
• Management has identified material weaknesses in internal control over financial reporting, which could lead to additional material misstatements and negatively impact financial reporting accuracy.

Risks

• Aspire has a limited operating history and a history of operating losses, with no assurance of achieving profitability or raising additional financing.
• Requires substantial additional financing to achieve its goals; failure to obtain capital could delay, limit, reduce, or terminate product development or commercialization efforts.
• Business depends on experienced and skilled personnel; inability to attract and integrate such personnel could hurt financial performance.
• Failure to adequately protect intellectual property rights could lead to loss of revenue and harm operations and growth prospects.
• The market price of common stock may be volatile and fluctuate substantially, causing investment value to decline.
• Changes in accounting principles or their interpretation/implementation may adversely affect reported results.
• Failure to meet Nasdaq continued listing standards could result in delisting, adversely affecting liquidity and market price, and exposing the company to litigation.
• Material weaknesses in internal control over financial reporting could result in additional material misstatements.
• Technology platforms and product candidates are based on novel technologies with unproven regulatory approval pathways, and may not gain market acceptance even if approved.
• Business is highly dependent on the success of high-dose sublingual aspirin, which requires significant additional clinical testing.
• Clinical development is lengthy, expensive, and uncertain; earlier trial results may not predict future outcomes, and trials may fail to demonstrate safety and efficacy.
• Product candidates may cause undesirable side effects, halting development, preventing approval, limiting commercial potential, or resulting in negative consequences.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Reliance on third parties to conduct clinical trials and manufacture products poses risks if they fail to perform or comply with regulations.
• Currently lacks an in-house marketing and sales organization and experience, which could limit product revenue if unable to establish capabilities or partnerships.
• International marketing of product candidates involves additional risks, including differing regulatory requirements, economic instability, and enforcement challenges.
• Faces significant competition from other biotechnology and pharmaceutical companies with greater resources.
• Employees, contractors, and partners may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Reliance on third-party manufacturers exposes the company to risks of supply chain disruptions, quality control issues, and regulatory non-compliance.
• Use of hazardous and biological materials by third-party manufacturers could lead to liability for damages.
• The price of common stock and warrants may fluctuate significantly due to various factors, including clinical trial results, regulatory actions, and financing efforts.
• Percentage ownership may be diluted by future issuances of capital stock.
• Resales of common stock by selling shareholders may cause the market price to fall.

Future Outlook

Aspire intends to submit a section 505(b)(2) NDA for its high-dose aspirin product in Q3 2025 and will seek fast-track approval. The company may propose a later clinical trial for further FDA applications, if needed, to evaluate pharmacodynamic effects on platelet inhibition. Additional clinical trials are planned to differentiate aspirin from standard oral aspirin based on TXB2 inhibition and gastrointestinal effects for other therapeutic indications. For testosterone, a patent application will be filed, with cGMP batch production and Phase One clinical testing in Q1/Q2 2026, followed by a pre-IND meeting in Q4 2026 and Phase Two testing. An NDA for testosterone is anticipated in Q4 2026 at the earliest, with an expected three-year approval process. Semaglutide formulation is in final phases, with a similar market timeline to testosterone. The company will continue to develop and market drugs and nutraceuticals using its sublingual delivery technology, exploring licensing and collaboration agreements. An omnibus patent covering other drugs and supplements is anticipated in Q3 2025. The company is actively searching for a permanent CEO.

Management Comments

• Management believes that both results (faster bloodstream entry and more significant impact on TxB2) from the aspirin clinical trial are very positive.
• Management believes that they will be able to demonstrate that the sublingual delivery of aspirin can be accomplished safely and effectively and improve patient outcomes.
• Management believes that the FDA would consider and even welcome a filing that is sufficient to support this novel mode of administration of certain aspirin products.
• Counsel has advised that the FDA would consider fast-track approval under 505(b)(2).

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Aspire's focus on novel sublingual delivery mechanisms for known drugs and supplements positions it within a niche that seeks to improve drug efficacy, dosage management, and response time, potentially addressing limitations of traditional oral administration like gastrointestinal toxicity. The market for aspirin, a century-old drug, is well-established, but Aspire aims to disrupt it with a faster-acting, sublingual formulation. The company faces competition from major pharmaceutical and biotechnology companies with significantly greater resources, and its success will depend on differentiating its products based on efficacy, safety, convenience, and price.

Comparison to Industry Standards

• Aspire's sublingual aspirin product demonstrated faster bloodstream entry and a more significant impact on TxB2 compared to standard oral aspirin, such as Bayer aspirin, Advil, and Tylenol, which are currently on the market.
• To the company's knowledge, there are currently no sublingual aspirin products on the market or listed in the FDA's Orange Book, suggesting a potential first-mover advantage in this specific delivery method.
• The development timeline for testosterone and semaglutide (NDA submission Q4 2026 earliest, 3-year approval process) is consistent with typical timelines for non-fast-track drug approvals in the biopharmaceutical industry, but Aspire's novel delivery method introduces additional regulatory uncertainty compared to standard formulations.

Management Changes

Corporate Governance

Legal Proceedings

• The former CEO of Instaprin Pharmaceuticals, Inc., Donald A. Milne III, was convicted on a conspiracy to commit securities fraud charge, which has tarnished the company's reputation. The SEC filed a complaint against him on May 29, 2019, and a judgment of $4,182,627 was issued on June 5, 2019.

Related Party Transactions

• The company has outstanding Working Capital Loans from the New Sponsor or its affiliates, or certain officers and directors, totaling $499,214 as of June 30, 2025, which are repayable upon Business Combination or from funds outside the Trust Account.
• Loan and Transfer Agreements with New Sponsor, SSVK Associates, LLC, Apogee Pharma, and Jinal Sheth resulted in $499,214 outstanding as of June 30, 2025.
• Subscription Agreements (First and Second) with New Sponsor, an affiliate, and investors, where investors contributed $1,500,000 to the New Sponsor, which then loaned the funds to PowerUp. $1,500,000 is owing under these agreements as of June 30, 2025.
• A Promissory Note Fee Agreement with the Sponsor for $1,000,000 (Modified Promissory Note Fee) is outstanding and payable upon the successful closing of a Business Combination.
• Notes payable to related parties, totaling $1,331,357 as of June 30, 2025, formalize working capital advances from officers and directors, with 20% OID and 5% exit fees.
• An administrative services fee of $10,000 per month is paid to an affiliate of the Original Sponsor for office space and administrative support, with $353,679 accrued as 'Due to affiliate' as of June 30, 2025.
• The Securities Purchase Agreement (Feb 17, 2025) involved Cobra Alternative Capital Strategies, LLC, an entity controlled by Aspire's former Director of Investor Relations, Lance Friedman, and Target Capital X LLC, for $3,750,000 in senior secured convertible debentures.
• The Blackstone Subscription Agreement (Dec 18, 2024) involved Blackstone Capital Advisors, Inc., also controlled by Lance Friedman, for a promissory note up to $500,000, with commitment shares issued upon Business Combination.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of convertible notes (up to 147 million shares) and the proposed reverse stock split, which could reduce their ownership percentage and per-share value. The substantial doubt about going concern and Nasdaq delisting risk pose a high risk of investment loss.
• **Creditors**: The company has significant outstanding debt, including secured convertible debentures and related-party notes. The security interest granted to debenture holders provides some protection, but the going concern doubt indicates elevated risk of default.
• **Employees/Management**: Recent changes in CEO and directors, along with the ongoing search for a permanent CEO, suggest potential instability. The equity incentive plan aims to attract and retain talent, but the company's financial health could impact morale and retention.
• **Customers**: Potential customers for sublingual aspirin and other products could benefit from novel delivery mechanisms, but the early stage of development and regulatory hurdles mean commercial availability is not assured. The caffeine products are already being sold online.

Next Steps

• Fund the second tranche of $1,000,000 from the convertible promissory notes on the day after this S-1 filing.
• Fund the third tranche of $2,250,000 from the convertible promissory notes upon the effectiveness of this Registration Statement.
• Hold a special meeting of stockholders on November 4, 2025, to solicit votes for the approval of issuing more than 19.99% of outstanding shares upon note conversion and the floor price.
• Seek shareholder approval to grant the Board discretionary authority to effect a reverse stock split (1-for-5 to 1-for-40 ratio) within one year of approval.
• Submit a section 505(b)(2) NDA for the high-dose sublingual aspirin product in Q3 2025 and seek fast-track approval.
• File an omnibus patent in Q3 2025 to extend intellectual property rights to cover other classes of drugs and supplements.
• File a PCT application on October 1, 2025, claiming priority to U.S. Application No. 63/702,381 for high-dose sublingual aspirin.
• Develop and validate the manufacturing process for sublingual testosterone in Q1/Q2 2026, and produce a cGMP batch for clinical testing and stability study.
• Conduct a Phase One clinical test for sublingual testosterone in approximately Q3 2026.
• Request a pre-IND meeting with the FDA for the testosterone product in Q4 2026, followed by Phase Two clinical testing.
• Submit an NDA for the testosterone product under 505(b)(2) to the FDA in Q4 2026 at the earliest.
• Continue final phases of developing a working formulation for a sublingual semaglutide product.
• Conduct a search for a permanent Chief Executive Officer.

Key Dates

Recommendation

Aspire Biopharma Holdings, Inc. is in a precarious financial position, evidenced by substantial recurring losses, a significant accumulated deficit, and a critical working capital deficit. Management has explicitly raised 'substantial doubt' about the company's ability to continue as a going concern. Furthermore, the company faces imminent Nasdaq delisting risks due to non-compliance with market value and bid price requirements. While there are positive developments in product pipeline and clinical trials, these are early-stage and do not offset the severe financial and operational risks. The current S-1 filing is for the resale of shares by existing investors, not a primary capital raise for the company, meaning it will not directly improve the company's liquidity. The potential for massive dilution from convertible notes and a proposed reverse stock split further exacerbates the risk for current and prospective investors. Given these overwhelming negative factors, a seasoned investor would likely recommend a strong sell.

Keywords

Biopharma, Sublingual Delivery, Aspirin, Pharmaceuticals, Supplements, SEC Filing, S-1, Convertible Notes, Going Concern, Nasdaq Delisting, Clinical Trials, Drug Development, Intellectual Property, Capital Raise, Biotechnology